FindTrial
Sign In

Specific post-marketing surveillance of pazufloxacin (Pasil), an injectable antimicrobial

Specific post-marketing surveillance of pazufloxacin (Pasil) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222732
Enrollment
300
Registered
2015-01-29
Start date
2015-01-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by Streptococcus pneumoniae

Interventions

investigational material(s) Generic name etc : pazufloxacin inj. INN of investigational material : pazufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for I

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Target disease: sepsis, severe or intractable respiratory tract infections (pneumonia, secondary infection of chronic respiratory diseases), or the pneumonia caused by Streptococcus pneumoniae 2. Age: 15 years of age and older 3. Gender : Both 4. Patients administered at a dose of 1,000 mg twice daily 5. Others

Exclusion criteria

Exclusion criteria: 1. Patients in whom drug efficacy of pazufloxacin (Pasil) was difficult to assess 2. Others

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026